MarketBeat
08 Aug 2026, 04:04 UTC · 8w ago
Ginkgo Bioworks Q2 Earnings Call Highlights
Impact · against what's priced in
Ginkgo Bioworks faces significant downward pressure due to a nearly 50% year-over-year collapse in revenue, which overshadows the tactical benefit of reduced cloud commitments and new academic lab contracts. While the company is pivoting toward autonomous lab systems, the current cash burn relative to declining revenue creates a precarious runway.
- DNA−0.60
No priced-in read yet
- In context
Revenue fell 48% year-over-year to $20 million, indicating a severe contraction during the pivot to autonomous labs. While the company reduced Google Cloud commitments by $100 million and secured several university contracts, these are offset by a net loss of $57 million and a continuing cash burn of $125M-$150M annually.
